Session Type
Meeting
Search Results for Alcohol Use Disorder
Oral Presentations
Abstract Number: 15
SHM Converge 2024
Background: Affecting approximately 5.9% of the US population, alcohol use disorder (AUD) has been established as a prevalent disease in this country (1). Through repeated hospital admissions for alcohol use disorder (including alcohol withdrawal syndromes), hospital costs have steadily risen to recent estimates of 7.6 billion dollars in 2017 (2). Without the establishment of outpatient […]
Oral Presentations
Abstract Number: 15
SHM Converge 2024
Background: Affecting approximately 5.9% of the US population, alcohol use disorder (AUD) has been established as a prevalent disease in this country (1). Through repeated hospital admissions for alcohol use disorder (including alcohol withdrawal syndromes), hospital costs have steadily risen to recent estimates of 7.6 billion dollars in 2017 (2). Without the establishment of outpatient […]
Abstract Number: 41
SHM Converge 2023
Background: Alcohol use disorder (AUD) is the most prevalent substance use disorder, but most patients with AUD do not receive evidence-based medications for AUD (MAUD), including naltrexone or acamprosate. Inpatient addiction consult services (ACS) may offer an opportunity to start medical treatment for hospitalized patients with AUD, but it is unknown if ACS are associated […]
Abstract Number: 145
SHM Converge 2024
Background: Alcohol use disorder (AUD) Is present in 10% of adults and its prevalence is increasing. When patients with AUD are admitted to the hospital, half develop alcohol withdrawal syndrome (AWS), which can cause delirium, hallucinations, seizures, and even mortality if not treated appropriately. A fixed-dose phenobarbital strategy may be superior to the standard of […]
Abstract Number: 211
Hospital Medicine 2020, Virtual Competition
Background: Up to 12% of hospitalized patients require high dose parenteral thiamine treatment to prevent Wernicke’s Encephalopathy, a devastating and easily preventable neurologic disorder that can lead to death. Despite the fact that it is as simple and relatively inexpensive therapy with no known side effects, high dose thiamine continues to be underutilized. Attempts to […]
Abstract Number: 226
SHM Converge 2024
Background: Alcohol use disorder (AUD) is a pervasive disease affecting 28.6 million (11.3%) American adults in 2021.1 Medications for AUD (MAUD), including naltrexone, acamprosate, and disulfiram, are effective, yet less than 5% of these patients received treatment.1,2 Inpatient encounters of patients with AUD present a crucial opportunity to initiate MAUD, prompting this quality improvement […]
Abstract Number: 368
SHM Converge 2023
Background: Approximately 5% of patients hospitalized at our institution develop clinically significant alcohol withdrawal syndrome (AWS). Inpatients who develop AWS may experience seizures, delirium, ICU transfer and prolonged length of stay. While the mortality of AWS, mostly related to delirium tremens, has decreased over time, severe alcohol withdrawal is still associated with a mortality of […]
Abstract Number: 402
Hospital Medicine 2020, Virtual Competition
Background: New Mexico has the highest number of alcohol-related deaths in the country, a title held since 1981. Nationally 1 in 10 deaths in working-aged adults are alcohol-associated whereas in New Mexico the ratio is 1 in 6 deaths. About 130,000 New Mexicans report alcohol dependence or abuse within the past year, but only 3% […]
Abstract Number: 405
SHM Converge 2024
Background: Between 5-30% of hospitalized patients screen positive for unhealthy alcohol use (UAU), and roughly 10-15% of patients have alcohol use disorder (AUD). Brief counseling and medications for AUD are shown to reduce alcohol consumption yet are underutilized in hospitals: over 90% of patients nationally are not screened and treated for UAU. Purpose: To increase […]
Abstract Number: 432
Hospital Medicine 2020, Virtual Competition
Background: Prevalence of alcohol use disorder (AUD) on inpatient medicine wards exceeds 40%. Only 50% of these patients develop alcohol withdrawal, of whom only 5-20% develop complicated alcohol withdrawal syndromes (AWS) that warrant treatment and monitoring. Overutilization of the Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar) scale is well-reported in the literature. CIWA-Ar […]